Indications
Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
Composition
- Active substance
- etelcalcetide hydrochloride
- International name (INN)
- etelcalcetide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Parsabiv
- Active substance
- etelcalcetide hydrochloride
- ATC code
- H05BX04
- Therapeutic area
- Hyperparathyroidism, Secondary
- Marketing authorisation holder
- Amgen Europe B.V.